breast cancer in the menopause anne gompel, geneviève plu-bureau and jean-michel foidart
TRANSCRIPT
![Page 1: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/1.jpg)
Breast cancerBreast cancerin the menopausein the menopause
Anne Gompel, Geneviève
Plu-Bureau and Jean-Michel Foidart
![Page 2: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/2.jpg)
*ASR = *ASR = age-standardized rate or age-adjusted
• 1,151,298 million newly diagnosed cases annually in the world– ASR* = 37.4/100,000/year
• 410,712 deaths from breast cancer– ASR* = 13.2/100,000/year
• 20–30% ofof all all cancerscancers in women in women
Breast cancer
http://www-dep.iarc.fr/
![Page 3: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/3.jpg)
Globally, breast cancer is the most Globally, breast cancer is the most prevalent cancer in women prevalent cancer in women
ASR (incidence): 37.7
ASR (deaths): 13.2 http://www-dep.iarc.fr/ Globocan 2002, IARC
Breast
Cervix uteri
Colon and rectum
Lung
Stomach
Ovary, etc.
Corpus uteri
Liver
Esophagus
Other
1151289 (22.7%)
493243 (9.7%)
472687 (9.3%)
386891 (7.6%)
330518 (6.5%)
204499 (4.0%)
198783 (3.9%)
184043 (3.6%)
146723 (2.9%)
1491972 (29.5%)
New cancer cases (all ages), females 5,060,657
![Page 4: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/4.jpg)
Socioeconomic status High Low
Oophorectomy < 40 years No Yes
Nulliparity Yes No
Age at first full-term pregnancy (years) ≥ 30 < 30
Age at menarche (years) ≤ 11 ≥ 15
Age at menopause (years) ≥ 55 < 45
Personal history of endometrial Yes Noor ovarian cancer
Obesity: postmenopausal breast cancer Obese Lean
Obesity: premenopausal breast cancer Lean Obese
Breast feeding (premenopausal cancer) > 12 months
Exercise > 2 hours/week
Risk factors, RR Risk factors, RR 1–21–2
High risk Low risk
![Page 5: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/5.jpg)
Follow-up (years) 6.8 6.2 7.1
RR of BC (ITT) 1.27 1.26 0.80
95% CI 0.8–1.9 1.0–1.60.62–1.04
RR of BC (adherent) 1.49 0.67
95% CI 1.13–1.960.47–0.97
HERS II WHI
Randomized, controlled trials: Randomized, controlled trials: resultsresults
E + P E + P E
Hulley JAMA 1998; Chlebowski JAMA 2002, JAMA 2003; Stefanick, JAMA 2006
![Page 6: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/6.jpg)
HT may promote pre-existing tumors HT may promote pre-existing tumors but does not induce new breast cancerbut does not induce new breast cancer
• In all recent studies, former HT users have no increased risk
• Breast cancer risk related to HT decreases rapidly after cessation of treatment
• HT increases the incidence of preinvasive (in situ) lesions in the Million Women Study in current users
![Page 7: Breast cancer in the menopause Anne Gompel, Geneviève Plu-Bureau and Jean-Michel Foidart](https://reader036.vdocuments.us/reader036/viewer/2022082505/56649f575503460f94c7cbc5/html5/thumbnails/7.jpg)
DensityDensity
• Spontaneous increased density: RR increased 3–6 times
• Density during HT– Edema– Stroma (androgens?)– No increase in proliferation
• Breasts with increased density : RR increased by a low sensitivity – Increase the frequency of
mammograms in US